Serum glucose concentration, triglycerides, total cholesterol, and high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol was measured.
It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure.
There was no significant difference between the two groups regarding gender, smoking habit, BMI, diastolic blood pressure, serum total, HDL and LDL cholesterol concentrations, triglyceride, and creatinine levels.
Fenofibrate predominantly decreased triglyceride concentrations (triglycerides, −39%; p <0.005) and induced a shift in LDL subtype distribution from small, dense LDL (−31%) to intermediate-dense LDL (+36%).
Concentration of triglycerides was measured using triglyceride Colorimetric Assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) according to manufacture's protocol.
Concentration of triglyceride in liquid phase (mol/l).
Initial concentration of triglyceride in liquid phase (mol/l).
Concentration of triglyceride on the interfacial solid liquid area (mol/l).
Secondly, data on blood lipids, hemoglobin A1C concentration, or triglyceride concentrations were unavailable, and therefore we could not use these measures for risk stratification or diagnostic purposes.
Three responses of total yield (TY), concentration of triglycerides (CTG) and recovery of triglycerides (RTG) were measured.
